News

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to 9 years, were included.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

Personalizing treatment options and setting realistic expectations are crucial.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

BRIMOCHOL PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

Katrina Ronne shares her vision to empower ophthalmologists, champion equity, and strengthen advocacy for better eye health outcomes across Australia.

Although it improved interdisciplinary communication, ongoing review and safety monitoring are necessary for successful clinical implementation.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset.

Each company will hold a respective special meeting of stockholders to vote on the approval of the merger.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.

In celebration of Ophthalmology Times' 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the past 5 decades.